





7 May 2024 **TEDD Visit to UPM Biomedicals** and CSEM at Switzerland **Innovation Park Basel Area** 

Allschwil, Switzerland







#### **About UPM Biomedicals**

UPM Biomedicals stands at the forefront of innovation in the production of high-quality nanofibrillar cellulose for medical and life science applications. With over 400 patents, birch pulp-derived nanofibrillar cellulose as a biomaterial sets new standards in biocompatibility, ease od use, and sustainability, offering a versatile foundation for a broad spectrum of scientific applications.

The 3D cell culture hydrogels and bioinks, GrowDex and GrowInk, closely mimic the extracellular matrix, supporting physiological cell functions and enabling the detailed study and modelling of both healthy and diseased tissue environments. Their seamless integration into research workflows, along with their animal-component-free composition, ensures a consistent, reproducible environment crucial for high-throughput screenings and 3D bioprinting, thereby boosting research efficiency and reliability.

Collaboration with global academic and industrial partners underscores UPM Biomedicals' commitment to pioneering solutions in tissue engineering, drug discovery, and personalized medicine, marking a significant shift towards more ethical, sustainable, and innovative research practices.

### About CSEM - Facing the challenges of our time

CSEM is a Swiss technology innovation center developing advanced technologies with a high societal impact, which it then transfers to industry to strengthen the economy. The non-profit orientated, public-private organization is internationally recognized, and works to support the disruptive activities of companies in Switzerland and abroad. CSEM operates in the domains of precision manufacturing, digitalization, and sustainable energy. To accomplish its mission as gateway between research and economy, CSEM's more than 600 employees from 46 countries collaborate with leading universities, scientific institutions, research institutes, and industrial partners. With its six sites in Allschwil, Alpnach, Bern, Landquart, Neuchâtel and Zurich, CSEM is active all over Switzerland.

CSEM is at the forefront of life sciences, combining engineering skills, biological understanding, and cutting infrastructure to revolutionize the field. By bridging precision manufacturing and digitalization, we develop disruptive biosystems that bring the lab to the patient and vice versa. From our advanced biosafety level 2 labs, we leverage cutting-edge technologies like cell microsystems, biomonitoring, lab automation, and AI to create impactful solutions. Our work narrows the gap between applied sciences and industrialization, enabling standardization and advancements for personalized medicine, diagnostics, and advancements in regenerative medicine. CSEM's tools for life sciences innovation are unlocking new possibilities in healthcare.

#### **About Switzerland Innovation Park Basel Area**

The Switzerland Innovation Park Basel Area a place where you can shape the future. It is part of Switzerland Innovation's network of science parks and has three sites: Main Campus, Novartis Campus and Jura. Each site of the Switzerland Innovation Park Basel Area is strategically designed to support specific sectors, enabling tailored support, resources, and networking opportunities for startups and established companies. This differentiation allows focused growth and development in key areas of innovation, contributing significantly to the region's reputation as a leading global hub for healthcare, life sciences, and technology.



# **Program**

9:30 - 10:00	Arrival, registration, coffee
10:00 - 10:30	Welcome address by TEDD, UPM, CSEM
10:30 - 10:50	Animal-Free Strategies for 3D Culture in Drug Discovery and Life Science Applications, Essi Niemi and Marlies Mürnseer, UPM
10:50 - 11:10	Tumor Organoids in Liver Cancer Drug Discovery: The New Frontier, Dr. Sandro Nuciforo, University of Basel
11:10 - 11:30	Enabling technologies empowering innovation in tissue engineering and cell assays – from organoids to single cells, Dr. Stéphanie Boder-Pasche, CSEM
11:30 - 11:50	Navigating Standardization and Automation in Cell Biology: Balancing Versality and Customization, Dr. Nadine Thaler, Hamilton
11:50 - 12:00	Group Photo
12.00 - 13:30	Networking lunch
13:30 - 15:00	CSEM Labs tour, UPM Biomedicals booth, and Switzerland Innovation Park Basel Area Main Campus tour
15.00 - 15.15	Closing words by TEDD, UPM, CSEM



# **Organisers**



**Essi Niemi**UPM Biomedicals



Marlies Mürnseer
UPM Biomedicals



Felix Kurth CSEM



Gilles Weder CSEM



Christoph Joder
CSEM



Markus Rimann
ZHAW/TEDD Competence Centre



Katarzyna Kopanska ZHAW/TEDD Competence Centre



## **Information**

### Cost

TEDD Partners (two participants)
3rd and next TEDD Partner
Others

No entrance fee CHF 40 CHF 80

### Registration

Opens 03 April 2024 Ends 02 May 2024





### Contact

Katarzyna Kopanska katarzyna.kopanska@zhaw.ch



### Location

### Switzerland Innovation Park Basel Area AG

Hegenheimermattweg 167A 4123 Allschwil, Switzerland


### From Basel SBB Railway Station (approx. 20 min)

- Bus No. 48 direction Bachgraben (the bus leaves behind the airport bus No. 50)
- Get off the bus at the bus stop "Kreuzstrasse"
- Walk down Hegenheimermattweg to the Main Campus
- Enter the inner courtyard/park and walk to entrance A

#### Car Park

- Public car park at Kreuzstrasse 4









## **About TEDD Competence Centre**

TEDD (Tissue Engineering for Drug Development and Substance Testing) is an education, R&D and networking platform promoting the application of 3D organotypic technologies, with the core goal of replacing animal experimentation for therapies development.

Based in Switzerland, TEDD is focused on 3D for 3Rs. The community is composed of international members from academia, clinics, industry and non-profits.

Training of members is achieved through regular events at the national and international level, including workshops, symposia, company visits, scientific reviews and we provide a platform to generate research consortia, projects and grant applications.

